AMZN
Amazon.com, Inc.
AMZN's fundamentals are mixed: revenue grew 15%, but free cash flow turned negative. Its PE of 22x looks cheaper than it really is, because one-off gains boosted its recent earnings. Analysts expect strong earnings growth.
NCI
Neo-Concept International Group Holdings Limited
There isn't enough reported data to score NCI yet.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
NCI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Stable | |
| Unavailable | |
| Strong |
NCI's balance sheet is currently strong, and its profitability is stable. There isn't enough data to rate its revenue and cash flow.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over NCI in the historical PE scenario, which offers more potential upside but is not a forecast.
NCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $4.21 | -18% |
| Current | 7.9x | $5.12 | — |
| Fair | 13x | $8.38 | +64% |
| Expensive | 107x | $69.87 | +1265% |
Historical ranges are pointers, not guarantees.
NCI's PE is 7.8x, but its earnings don't support one, so it isn't a reliable read right now.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
NCI Forward outlook
There aren't enough analyst estimates for NCI to show an outlook.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over NCI in the latest year-over-year earnings comparison.
NCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.65 | -96% |
| Q4 2024 | $16.71 | +64% |
| Q4 2023 | $10.19 | -64% |
| Q4 2022 | $28.08 | +128% |
NCI's earnings per share have fallen from their peak: $0.65 over the past year, against $35.52 in mid-2022.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
NCI has the stronger quarterly revenue trend. Revenue is up 12% for AMZN versus up 77% for NCI.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN's operating margin was 14% last quarter, up 4.2 points from the same quarter a year ago, near the top of its range since 2019.
NCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $17.5M | -42% |
| Q4 2024 | $30M | +35% |
| Q4 2023 | $22.2M | +125% |
| Q4 2022 | $9.9M | -7.4% |
| Q3 2022 | $9.9M | -7.4% |
| Q2 2022 | $12.2M | +164% |
| Q1 2022 | $12.2M | +164% |
NCI's revenue is growing: $17M last quarter, up 77% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 1.3% | -1.6 points |
| Q4 2024 | 4.9% | -2.5 points |
| Q4 2023 | 5.2% | -2.3 points |
| Q4 2022 | 3% | -0.4 points |
| Q3 2022 | 3% | -0.4 points |
| Q2 2022 | 7.5% | +9 points |
| Q1 2022 | 7.5% | +9 points |
| Q4 2021 | 3.3% | N/A |
NCI's operating margin was 1.3% last quarter, down 1.6 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
NCI has the stronger cash trend. Its trailing FCF is down 156% versus its history, compared with AMZN at down 619%.
NCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $2.2M | +$2.7M |
| Q4 2024 | -$473.3K | +$6M |
| Q4 2023 | -$6.4M | -$1.6M |
| Q4 2022 | -$4.8M | -883% |
| Q3 2022 | -$4.8M | -883% |
| Q2 2022 | $2.1M | +5597% |
| Q1 2022 | $2.1M | +5597% |
NCI's free cash flow was −$9M over the past year, against −$45,684 the year before.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has the edge over NCI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
NCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.7% | +2.2K shares |
| 1 year | +13% | +7.3K shares |
NCI has 63,500 diluted shares, up 13% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.4x | Very low |
| Q4 2024 | 1.3x | Healthy |
| Q4 2023 | 2.7x | Moderate |
| Q4 2022 | 4.0x | Elevated |
| Q2 2022 | 1.4x | Healthy |
| Q4 2021 | 5.8x | High |
NCI's net debt is less than a year of its operating earnings (EBITDA), down from 1.4 years a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
NCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.9 | Neutral |
| Stochastic | 1.9 | Oversold |
NCI's weekly RSI is 34 (neutral) and its Stochastic is 2 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
NCI PE vs Consumer Cyclical Sector
| Metric | NCI | Sector median | Relative |
|---|---|---|---|
| PE | 7.9x | 18x | 56% below |
| PE % | 34 | 24 | 10 pts above |
NCI has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has stronger trend alignment. AMZN is above 5 of 5 weekly averages versus NCI above 0 of 4.
NCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.7 | 74% below |
| 20 week MA | $67.8 | 92% below |
| 50 week MA | $117.5 | 96% below |
| 100 week MA | $125.3 | 96% below |
NCI is in a downtrend: it's below all four of its weekly moving averages, and 96% below its 100-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over NCI on returns for 2026, with the stronger performance.
NCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $601.6 | $167.0 | -72% |
| 2025 | $167.0 | $78.1 | -53% |
| 2026 YTD | $78.1 | $5.12 | -93% |
NCI has finished every year since 2024 lower, and it's down 93% so far in 2026.